Literature DB >> 26681761

NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.

Nicolas Duployez1, Guillaume Grzych2, Benoît Ducourneau2, Martin Alarcon Fuentes3, Nathalie Grardel2, Thomas Boyer4, Wadih Abou Chahla3, Bénédicte Bruno3, Brigitte Nelken3, Emmanuelle Clappier5, Claude Preudhomme4.   

Abstract

Entities:  

Keywords:  B-cell precursor acute lymphoblastic leukemia; BCR-ABL1-like; adolescents; tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2015        PMID： 26681761      PMCID： PMC5004396          DOI： 10.3324/haematol.2015.136499

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.

Authors:  C Graux; J Cools; C Melotte; H Quentmeier; A Ferrando; R Levine; J R Vermeesch; M Stul; B Dutta; N Boeckx; A Bosly; P Heimann; A Uyttebroeck; N Mentens; R Somers; R A F MacLeod; H G Drexler; A T Look; D G Gilliland; L Michaux; P Vandenberghe; I Wlodarska; Peter Marynen; Anne Hagemeijer
Journal:  Nat Genet       Date:  2004-09-12       Impact factor: 38.330

2.  Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment.

Authors:  K Stergianou; C Fox; N H Russell
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

3.  Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.

Authors:  W Deenik; H B Beverloo; S C P A M van der Poel-van de Luytgaarde; M M Wattel; J W J van Esser; P J M Valk; J J Cornelissen
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

4.  Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

Authors:  Etienne Lengline; Kheïra Beldjord; Hervé Dombret; Jean Soulier; Nicolas Boissel; Emmanuelle Clappier
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

5.  Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.

Authors:  K De Keersmaecker; M Versele; J Cools; G Superti-Furga; O Hantschel
Journal:  Leukemia       Date:  2008-09-11       Impact factor: 11.528

Review 6.  ABL1 fusion genes in hematological malignancies: a review.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; David Rowe; Nick Bown; Frédéric Morel; Christian Berthou; Claude Férec; Marc De Braekeleer
Journal:  Eur J Haematol       Date:  2011-03-23       Impact factor: 2.997

7.  Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia.

Authors:  P Ruminy; V Marchand; N Buchbinder; T Larson; B Joly; D Penther; E Lemasle; S Lepretre; E Angot; S Mareschal; P-J Viailly; S Dubois; F Clatot; M Viennot; E Bohers; D Rizzo; M Cornic; P Bertrand; C Girod; V Camus; P Etancelin; G Buchonnet; P Schneider; J-M Picquenot; J-P Vannier; C Bastard; H Tilly; F Jardin
Journal:  Leukemia       Date:  2015-07-03       Impact factor: 11.528

8.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.

Authors:  Monique L Den Boer; Marjon van Slegtenhorst; Renée X De Menezes; Meyling H Cheok; Jessica G C A M Buijs-Gladdines; Susan T C J M Peters; Laura J C M Van Zutven; H Berna Beverloo; Peter J Van der Spek; Gaby Escherich; Martin A Horstmann; Gritta E Janka-Schaub; Willem A Kamps; William E Evans; Rob Pieters
Journal:  Lancet Oncol       Date:  2009-01-08       Impact factor: 41.316

9.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Yongjin Li; Debbie Payne-Turner; Richard C Harvey; Yung-Li Yang; Deqing Pei; Kelly McCastlain; Li Ding; Charles Lu; Guangchun Song; Jing Ma; Jared Becksfort; Michael Rusch; Shann-Ching Chen; John Easton; Jinjun Cheng; Kristy Boggs; Natalia Santiago-Morales; Ilaria Iacobucci; Robert S Fulton; Ji Wen; Marcus Valentine; Cheng Cheng; Steven W Paugh; Meenakshi Devidas; I-Ming Chen; Shalini Reshmi; Amy Smith; Erin Hedlund; Pankaj Gupta; Panduka Nagahawatte; Gang Wu; Xiang Chen; Donald Yergeau; Bhavin Vadodaria; Heather Mulder; Naomi J Winick; Eric C Larsen; William L Carroll; Nyla A Heerema; Andrew J Carroll; Guy Grayson; Sarah K Tasian; Andrew S Moore; Frank Keller; Melissa Frei-Jones; James A Whitlock; Elizabeth A Raetz; Deborah L White; Timothy P Hughes; Jaime M Guidry Auvil; Malcolm A Smith; Guido Marcucci; Clara D Bloomfield; Krzysztof Mrózek; Jessica Kohlschmidt; Wendy Stock; Steven M Kornblau; Marina Konopleva; Elisabeth Paietta; Ching-Hon Pui; Sima Jeha; Mary V Relling; William E Evans; Daniela S Gerhard; Julie M Gastier-Foster; Elaine Mardis; Richard K Wilson; Mignon L Loh; James R Downing; Stephen P Hunger; Cheryl L Willman; Jinghui Zhang; Charles G Mullighan
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

10.  Autoinhibition of Bcr-Abl through its SH3 domain.

Authors:  Kristen M Smith; Rinat Yacobi; Richard A Van Etten
Journal:  Mol Cell       Date:  2003-07       Impact factor: 17.970
  10 in total
  12 in total

1.  Clinico-Hematological Profile and Copy Number Abnormalities in a Cohort of STIL-TAL1 and NUP214-ABL1 Positive Pediatric T-Cell Acute Lymphoblastic Leukemia.

Authors:  Nilamani Patra; Minu Singh; Pankaj Sharma; Amita Trehan; Shano Naseem; Deepak Bansal; Prateek Bhatia
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-25       Impact factor: 0.915

2.  Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.

Authors:  Valentina Nardi; Steven L McAfee; Paola Dal Cin; Harrison K Tsai; Philip C Amrein; Gabriela S Hobbs; Andrew M Brunner; Rupa Narayan; Julia Foster; Amir T Fathi; Hanno Hock
Journal:  Oncologist       Date:  2022-03-04       Impact factor: 5.837

3.  Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.

Authors:  Carolina Simioni; Simona Ultimo; Alberto M Martelli; Giorgio Zauli; Daniela Milani; James A McCubrey; Silvano Capitani; Luca M Neri
Journal:  Oncotarget       Date:  2016-11-29

4.  Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia.

Authors:  Jess F Peterson; Beth A Pitel; Stephanie A Smoley; James B Smadbeck; Sarah H Johnson; George Vasmatzis; Sarah J Koon; Matthew R Webley; Mary McGrath; Michael G Bayerl; Linda B Baughn; Ross A Rowsey; Rhett P Ketterling; Patricia T Greipp; Nicole L Hoppman
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-04-01

5.  Rapid Identification of Key Copy Number Alterations in B- and T-Cell Acute Lymphoblastic Leukemia by Digital Multiplex Ligation-Dependent Probe Amplification.

Authors:  Deepshi Thakral; Gurvinder Kaur; Ritu Gupta; Anne Benard-Slagter; Suvi Savola; Indresh Kumar; Rajni Anand; Lata Rani; Pramod Verma; Sangeeta Joshi; Lalit Kumar; Atul Sharma; Sameer Bakhshi; Rachna Seth; Vivek Singh
Journal:  Front Oncol       Date:  2019-09-13       Impact factor: 6.244

6.  Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion.

Authors:  Gauthier Decool; Carine Domenech; Nathalie Grardel; Adriana Plesa; Imelda Raczkiewicz; Benoit Ducourneau; Philippe Ruminy; Marie-Pierre Pages; Sandrine Girard; Laurène Fenwarth; Claude Preudhomme; Yves Bertrand; Nicolas Duployez
Journal:  Hemasphere       Date:  2019-06-04

7.  Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing.

Authors:  Huan-Ping Wang; Jun-Jun He; Qiao-Yun Zhu; Lin Wang; Jian-Hu Li; Jian-Song Huang; Wan-Zhuo Xie; Hong-Hu Zhu; Jie Jin
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

Review 8.  New biological and genetic classification and therapeutically relevant categories in childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Jan Starý; Jan Zuna; Marketa Zaliova
Journal:  F1000Res       Date:  2018-09-28

Review 9.  The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.

Authors:  Parveen Shiraz; Kimberly J Payne; Lori Muffly
Journal:  Int J Mol Sci       Date:  2020-03-22       Impact factor: 5.923

Review 10.  The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.

Authors:  Paniz Tavakoli Shirazi; Laura N Eadie; Susan L Heatley; Timothy P Hughes; David T Yeung; Deborah L White
Journal:  Br J Cancer       Date:  2019-12-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.